RxDoctor Payments Data

Revery Barnes, MD

Family Medicine · Los Angeles, CANPI 1669812467

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,720 of the $2,579 with a category attached, or 66.7%. Gilead accounts for 80.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $1,899 and has fallen 88.9% since, to $212 in 2025.

$2,579in general payments, 2019–2025

Across 61 payments — averaging $42.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Viiv Healthcare Company$398
  • Merck$72
  • Johnson & Johnson$28

What the payments were for

  • Consulting fees$1,72067%
  • Food & beverage$81432%
  • Education$452%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead42$2,081
Viiv Healthcare Company14$398
Merck4$72
Johnson & Johnson1$28

How this compares

$2,579 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California →

Medicare billing

Part B allowed, 2024
$43,568
Medicare patients
45
Services billed
1,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala264$985,565
JulucaDolutegravir/Rilpivirine68$222,487
DovatoDolutegravir Sodium/Lamivudine38$102,382
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf22$95,010
OdefseyEmtricitab/Rilpiviri/Tenof Ala25$83,914
TivicayDolutegravir Sodium26$55,643
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$42,252
OzempicSemaglutide45$39,502
PrezcobixDarunavir/Cobicistat15$32,439
JardianceEmpagliflozin22$11,605
EliquisApixaban20$11,034
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$8,600
XareltoRivaroxaban12$6,147
Incruse ElliptaUmeclidinium Bromide11$3,515
Insulin Lispro Kwikpen U-100Insulin Lispro12$3,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$2,081$1,027,816276 claims
Viiv Healthcare CompanyJuluca, Dovato, Tivicay$398$380,513132 claims
Johnson & JohnsonPrezcobix, Xarelto$28$38,58627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →